Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
May 01 2024 - 8:30AM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
announced today that Jeff Ehrhardt has joined the company as
General Manager of North America. After having spent over 25 years
at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins
Establishment Labs with responsibilities including the anticipated
launch of Motiva implants in the U.S. later this year.
“Jeff is the ideal person to introduce Motiva to the United
States,” said Juan José Chacón-Quirós, CEO and Founder of
Establishment Labs. “Just as we have changed the standard for
breast augmentation and reconstruction around the world for more
than a decade, we will establish a new standard for women and
plastic surgeons in the United States. With Jeff leading our
efforts, we expect to become the leading technology not only in the
U.S., but globally."
Mr. Ehrhardt was most recently General Manager for Plastic
Surgery & Regenerative Medicine at Allergan Aesthetics. In his
most recent role, Jeff was responsible for the company’s portfolio
of implants and related technologies in breast augmentation and
reconstruction, including developing and executing the group’s
commercial strategy and managing the U.S. sales and marketing
organizations. He has held a number of other positions at Allergan,
including vice president of U.S. operations, vice president of
sales, regional sales director, marketing director, sales training
director, sales rep, and roles in business development. Prior to
Allergan, Mr. Ehrhardt also worked at American Cyanamid and Johnson
& Johnson. Mr. Ehrhardt received his bachelor’s degree in
business from the University of Cincinnati and his MBA from Xavier
University.
"Joining Establishment Labs is in many ways the culmination of
the last 25 years of my career,” said Jeff Ehrhardt. “I’ve seen
firsthand the diminished importance of science and data in the U.S.
market. The lack of innovation has left plastic surgeons with few,
if any, real choices for technologies that can improve the outcomes
of their breast procedures. Establishment Labs is different. The
quality of the science and the outcomes achieved with Motiva
implants are unprecedented. We will not only take share, but also
have the potential to grow these markets as we show what can be
achieved when a company puts women at the center of everything that
it does.”
Establishment Labs' Motiva silicone gel-filled implants are
currently not approved for commercial distribution in the United
States. The Company’s implants are undergoing PMA clinical
investigation pursuant to U.S. FDA regulations for investigational
medical devices.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The over three million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is used to
improve outcomes in breast reconstruction following breast cancer
and it is the only regulatory-approved expander in the world with
an integrated port using radio-frequency technology that is MRI
conditional. Mia Femtech™, Establishment Lab’s unique minimally
invasive experience for breast harmony, is the Company’s most
recent breakthrough innovation. These solutions are supported by
over 200 patent applications in 25 separate patent families
worldwide and over 50 scientific studies and publications in peer
reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP
program. In 2018, the Company received an investigational device
exemption (IDE) from the FDA for Motiva Implants® and began a
clinical trial to support regulatory approval in the United States.
Please visit our website for additional information at
www.establishmentlabs.com.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). You can find many (but not all) of
these statements by looking for words such as “approximates,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “intends to,” “would,” “will,” “may” or other similar
expressions in this press release. Any statements that refer to
projections of our future financial or operating performance,
anticipated trends in our business, our goals, strategies, focus
and plans, including related product development and
commercialization and regulatory approvals, and other
characterizations of future events or circumstances, including
statements expressing general optimism about future operating
results, related to the company’s performance are forward-looking
statements. We claim the protection of the safe harbor contained in
the Private Securities Litigation Reform Act of 1995. We caution
investors that any forward-looking statements presented in this
report, or that we may make orally or in writing from time to time,
are expressions of our beliefs and expectations based on currently
available information at the time such statements are made. Such
statements are based on assumptions, and the actual outcome will be
affected by known and unknown risks, trends, uncertainties, and
factors that are beyond our control. Although we believe that our
assumptions are reasonable, we cannot guarantee future performance,
and some will inevitably prove to be incorrect. As a result, our
actual future results and the timing of events may differ from our
expectations, and those differences may be material. Factors, among
others, that could cause actual results and events to differ
materially from those described in any forward-looking statements
include risks and uncertainties relating to: our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product offerings;
the rate of adoption of our products by healthcare providers or
other customers; the success of our marketing initiatives; the safe
and effective use of our products; our ability to protect our
intellectual property; our future expansion plans and capital
allocation; our ability to expand upon and/or secure sources of
credit or capital; our ability to develop and maintain
relationships with qualified suppliers to avoid a significant
interruption in our supply chains; our ability to attract and
retain key personnel; our ability to scale our operations to meet
market demands; the effect on our business of existing and new
regulatory requirements; and other economic and competitive
factors. These and other factors that could cause or contribute to
actual results differing materially from our expectations include,
among others, those risks and uncertainties discussed in the
company’s annual report on Form 10-K filed on March 4, 2024, which
risks and uncertainties may be updated in the future in other
filings made by the company with the Securities and Exchange
Commission. The risks included in those documents are not
exhaustive, and additional factors could adversely affect our
business and financial performance. We operate in a very
competitive and rapidly changing environment. New risk factors
emerge from time to time, and it is not possible for us to predict
all such risk factors, nor can we assess the impact of all such
risk factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
We are not undertaking any obligation to update any forward-looking
statements. Accordingly, investors should use caution in relying on
past forward-looking statements, which are based on known results
and trends at the time they are made, to anticipate future results
or trends.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501035044/en/
Investor/Media Contact: Raj Denhoy 415 828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Oct 2023 to Oct 2024